Akari Therapeutics PLC (AKTX)

Akari Therapeutics PLC (AKTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $21.2M; returns 1 day +1.5%, 1 week +0.6%, 1 year -72.2%.

Akari Therapeutics PLC is a clinical-stage biotechnology company that, following a merger with Peak Bio Inc. in November 2024, has strategically pivoted to focus on the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company currently generates no revenue from product sales and operates as a pre-commercial R&D entity.

Groups AKTX belongs to

• Recent Reverse Splits
• Clinical Stage Biotech
• Biotechnology
• Antibody-Drug Conjugates
• Oncology
• Cancer Therapeutics
• Healthcare
• R&D
• Strategic Pivot
• Biopharmaceutical

AKTX financial model: income statement, cash flow and balance sheet